Hims & Hers Health surged 8.7% Friday to $29.32 after Bank of America Securities boosted its price target by 19.0%, signaling growing confidence in the telehealth platform’s growth trajectory.
The upgrade fueled momentum. B of A Securities maintained its Neutral rating but raised its price target from $21 to $25, a substantial upward revision that suggests the firm sees improving fundamentals even while stopping short of a full endorsement. The new target represents the analyst’s updated view on valuation for the specialty pharmaceutical company, which operates a direct-to-consumer telehealth model offering prescription medications and wellness products. The single upgrade was enough to drive significant investor interest in the $6.7B company.
Volume told the story. Trading activity surged to 22.8M shares, well above typical levels and confirming that institutional players were repositioning following the analyst action. The elevated volume suggests the price target increase resonated with investors who may have been waiting for Wall Street validation of the stock’s recent performance. At its current price of $29.32, the stock is trading well above the new $25 target, indicating that the market may be pricing in expectations that exceed the analyst’s near-term view.
The setup matters. Hims & Hers operates in the competitive specialty and generic drug manufacturing space, but its direct-to-consumer telehealth model differentiates it from traditional pharmaceutical distributors. The company has been expanding its product offerings and building brand recognition in a market where convenience and discretion drive consumer choices. Bank of America’s willingness to raise its target by nearly one-fifth suggests the firm sees sustainable momentum in the business model, even if it hasn’t yet upgraded to a Buy rating.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.